{"id":"NCT01081769","sponsor":"Janssen-Cilag International NV","briefTitle":"Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics","officialTitle":"A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2010-03-05","resultsPosted":"2015-02-18","lastUpdate":"2015-02-18"},"enrollment":769,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"paliperidone palmitate injection","otherNames":[]},{"type":"DRUG","name":"oral antipsychotics","otherNames":[]}],"arms":[{"label":"Paliperidone Palmitate","type":"EXPERIMENTAL"},{"label":"Oral Antipsychotics","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered antipsychotics in monotherapy over 24 months in the treatment of recently diagnosed (1-5 years since diagnosis) schizophrenia.","primaryOutcome":{"measure":"Time to First Relapse Event","timeFrame":"from baseline (Day 1 of core phase) up to maximally 24 months.","effectByArm":[{"arm":"Paliperidone Palmitate","deltaMin":616,"sd":10.9},{"arm":"Oral Antipsychotics","deltaMin":603,"sd":13.1}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0191"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":94,"countries":["Austria","Belgium","Bulgaria","Croatia","Czechia","Egypt","Estonia","France","Germany","Greece","Hungary","Israel","Jordan","Lithuania","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37756123"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":376},"commonTop":["Weight increased","Insomnia","Headache","Nasopharyngitis","Anxiety"]}}